Publication | Open Access

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Metastatic Urothelial CancerUrologyGenitourinary CancerSelect Fgfr AlterationsMedicineErdafitinib Versus PembrolizumabCancer TreatmentOncologyRadiation OncologyMolecular Oncology